Charles Nemeroff, MD
Psychiatry · Austin, TXNPI 1326228347
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $380,532 of the $428,591 with a category attached, or 88.8%. 19 manufacturers reported payments, led by Sage Therapeutics, LLC at 48.6% of the total. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 191 payments — averaging $2243.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sage Therapeutics, LLC$208K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$145K
- H. Lundbeck A S$16K
- Mylan Inc.$10K
- Janssen Scientific Affairs, LLC$10K
- Livanova USA, Inc.$8K
- plus $31K from 13 others
What the payments were for
- Consulting fees$380,53289%
- Speaking & faculty fees$26,2506%
- Travel & lodging$17,1754%
- Food & beverage$4,6341%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sage Therapeutics, LLC | 68 | $208,262 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 57 | $145,000 |
| H. Lundbeck A S | 2 | $16,400 |
| Mylan Inc. | 10 | $10,061 |
| Janssen Scientific Affairs, LLC | 3 | $9,565 |
| Livanova USA, Inc. | 6 | $8,228 |
| Acadia Pharmaceuticals Inc | 9 | $7,429 |
| SK Life Science, Inc. | 4 | $4,800 |
| Supernus Pharmaceuticals, Inc. | 1 | $3,500 |
| AbbVie(2 entities) | 3 | $3,400 |
| Almatica Pharma LLC | 9 | $3,255 |
| Bioxcel Therapeutics, Inc. | 1 | $2,680 |
| Alfasigma USA, Inc. | 2 | $2,448 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 9 | $1,991 |
| Corcept Therapeutics | 3 | $1,425 |
| Tris Pharma Inc | 1 | $65 |
| Jazz Pharmaceuticals Inc. | 1 | $37 |
| Biogen | 1 | $29 |
| Janssen Research & Development, LLC | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CAPLYTA$145,000
- REXULTI$18,114
- VNS Therapy Symmetry Model 8103 Generator$8,170
- NUPLAZID$5,673
- Cenobamate$3,200
- LOREEV XR$3,036
- IGALMI$2,680
- ABILIFY MAINTENA$2,000
- BRINTELLIX$2,000
- XCOPRI$1,600
- Korlym$1,425
How this compares
$428,591 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AuvelityDextromethorphan Hbr/Bupropion | 14 | $14,628 |
| CaplytaLumateperone Tosylate | 14 | $9,560 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 13 | $916 |
| Quetiapine Fumarate | 13 | $881 |
| Clonazepam | 31 | $435 |
| Lorazepam | 15 | $235 |
| Trazodone Hcl | 14 | $234 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $145,000 | $9,56014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,238 psychiatry providers in Texas.
Other psychiatry in Austin
- Arvinder Pal WaliaAustin$2.5M
- Divyansu PatelAustin$50K
- Rakesh JainLake Jackson$7.2M
- Suresh SureddiPlano$2.2M
- Martin GuerreroEl Paso$2M
- Marty BennettAddison$1.8M
- Matthew BramsHouston$1.5M
- Vikram MehraKaty$1.2M
- Joel HolinerDallas$948K
- Frank ChenHouston$941K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.